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During the in vivo predictive dissolution (iPD) – oral drug delivery (ODD) conference at Lake Tahoe from March 4-9, 2018, different speakers quoted 
the need of a biorelevant dissolution test to better 
reflect the intraluminal behavior of an oral drug product 
in the human gastrointestinal (GI) tract. All attendees 
agreed that replacement of human bioequivalence (BE)/ 
bioavailability (BA) studies by a biorelevant dissolution 
test will result in a more rational selection of drug and 
formulation strategies in the pharmaceutical industry, 
resulting in time- and cost-effective research, which is a 
benefit for pharmaceutical companies and, in the end, 
patients. There is a tremendous need to create a more 
scientific framework to assess formulation performance 
with less ethical considerations supporting novel and 
generic drug product development. Invited guest speakers 
discussed their personal expertise in the field of oral drug 
product testing. The ongoing biopharmaceutical project 
OrBiTo (http://www.orbitoproject.eu) kicked off in 2012 in 
Europe to address the pharmaceutical companies’ quest 
to improve the predictive power of in vitro dissolution 
methodologies. The structure and organization of the 
project was summarized by Hans Lennernäs. In addition, 
the first day discussed the different in vivo methodologies 
that can be applied to elucidate the behavior of on oral 
dosage form in the human GI tract with a specific focus 
on (i) aspiration/manometry studies (Gordon L. Amidon) 
and (ii) magnetic resonance imaging (MRI) studies 
(Luca Marciani). In the end, the compatibility of using a 
customized catheter with an MRI device is interesting to 
simultaneously explore the volumes present in the GI tract 
and back-and-forth mixing of fluids during intraluminal 
profiling studies. Another option is to apply the wireless 
pharmaceutical analysis device (WiPAD) that is currently 
being tested in dogs as presented by Duxin Sun. Briefly, 
a GI sampling capsule has to be orally ingested together 
with a drug product of interest. During its residence time 
in the GI tract, this capsule has the ability to take eight 
fluid samples at eight different regions inside the GI tract. 
After being emptied in the stool, the capsule can be 
recovered, opened, and the eight separated samples can 
be isolated and analyzed for drug content. This promising 
methodology is a less-invasive procedure compared 
to intubation studies, but development is still in the 
exploratory phase. The potential of applying positron-
emission tomography (PET) was explained by Shinji 
Yamashita, who compared concentrations of radiolabeled 
probes, e.g., [11C]telmisartan, in different tissues. This 
technique showed drug distribution of the radio-labeled 
drug along the GI tract of a rat and human (1). 
The second day of the conference focused on different 
physiological aspects of the GI tract that should not be 
neglected when it comes to biorelevant dissolution 
testing. Different talks made the audience aware that (i) 
selection of the right buffer/buffer concentrations (Gordon 
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L. Amidon and Gregory E. Amidon) and (ii) an adequate 
implementation of gastric motility and emptying ( Marival 
Bermejo and Paulo Paixão) are two critical parameters 
that should not be neglected if you want to draw the 
right conclusions related to drug product behavior in the 
human GI tract (2). The complexity of the stomach shows 
us that we would oversimplify the stomach whenever 
we would treat it as a single, well-mixed compartmental 
model. Based on intraluminal concentration-time 
profiles of the non-absorbable marker, phenol red, it 
became clear that the observed results along the GI 
tract can only be explained if the stomach is handled as 
a multi-compartmental design, respecting the stomach’s 
anatomy and physiology in fasted and fed states. Deanna 
Mudie (Lonza Pharma & Biotech) summarized the 
important in vitro dissolution parameters that should 
be considered to set up a biorelevant dissolution test for 
poorly soluble drug compounds in industry based on dose 
number, dissolution number, and permeation number 
(3). Especially for predictions towards the intraluminal 
behavior of poorly soluble drugs with basic properties, a 
lot of in vitro work has been established throughout the 
years working with the GI simulator (GIS) and artificial 
stomach-duodenum (ASD) model, as shown by the last 
presentation of the day by Yasuhiro Tsume (4–6). 
Day 3 of the conference presented academic and industry 
perspectives of performing biorelevant dissolution 
tests to select the right formulation(s) prior to the start 
of clinical trials. Ping Gao (AbbVie) and Deanna Mudie 
demonstrated the added value of a biphasic dissolution 
test (using an organic layer to mimic intestinal uptake of 
the drug) (7–9). Shinji Yamashita showed a quantitative 
assessment of oral drug absorption by working with 
an in vitro dissolution/permeation device (10). David 
C. Sperry (Eli Lilly and Company) demonstrated the 
practical use of combining biorelevant dissolution testing 
(performed in the ASD model) with physiologically-
based pharmacokinetic (PBPK) modeling to gain more 
information about drug product’s behavior in humans 
(11, 12). Moreover, the application of PBPK modeling to 
look at drug-drug interactions (DDI) is becoming a popular 
strategy in a regulatory context; from July 2008 until June 
2010, the United States Food and Drug Administration 
(FDA) reviewed seven investigational new drug (IND) 
products and six new drug products applications (NDA). 
Before 2008, the FDA received only two submissions 
containing PBPK modeling (13). Many of the PBPK 
modeling and simulation evaluations were addressing 
questions related to DDI and specific populations (e.g., 
pediatrics), which were described by Jianghong Fan of 
the FDA. From 2008 until 2015, the FDA received a total 
of 54 in vivo-in vitro correlations (IVIVC) submissions 
for NDA/IND approval; from the 54 submissions, 36 
regulatory submissions containing IVIVC approaches 
were not accepted and, consequently, failed approval. 
The development and incorporation of biopredictive 
dissolution methods should be explored to increase the 
likelihood of IVIVC success (14). 
On the fourth day, Raimar Löbenberg demonstrated how 
we should shift toward a more mechanistical product 
development with a scientific framework that supports 
IVIVC for different kinds oral drug formulations. He 
highlighted the benefit of coupling biorelevant dissolution 
testing with PBPK modeling to simulate the systemic 
outcome of oral drug products and to evaluate BE 
between tested and reference/marketed drug products. 
Greg Amidon, Niloufar Salehi, and James G. Brasseur 
showed us the impact of hydrodynamic enhancements 
on the dissolution rate of a drug. The application of 
computational fluid dynamics (CFD) for different in 
vitro models was illustrated and compared with in vivo 
shear rates (i.e., the rate at which a progressive shearing 
deformation is applied to some material) (15). This work 
clearly demonstrates the relevance of using the right 
dissolution vessel and impeller to create biorelevant 
conditions in terms of hydrodynamics. In addition to 
this work, a mass transport model (MTM) based on the 
design of the GIS was developed  to consider shear rates 
in different GI compartments. This model is a work in 
progress that, besides shear rates, also includes other 
physiological variables such as buffer properties, gastric 
emptying, pH, and secretions, as presented by Yasuhiro 
Tsume. The sensitivity of the integrated parameters can 
be essential to address potential BE failures whenever the 
marketed and tested drug product will be explored in the 
in vitro and in silico GIS device. This model expands the 
horizons to develop a scientific framework to evaluate 
IVIVC/IVIVR. Jack Cook (Pfizer) presented a survey that 
was conducted among 13 pharmaceutical companies 
(industry partners of the European IMI-funded project 
OrBiTo) to ask them about the current status of IVIVC 
development in pharmaceutical industry. The survey 
highlighted a lack of experience with respect to safe-
space in vivo-in vitro relationships (IVIVR) as well as the 
use of PBPK in the field of IVIVC. At the same time, the 
responses from both industry and regulatory agencies 
indicated that there might be a need for regulatory 
framework to guide the application of these novel 
approaches (16). The conclusion of this survey clearly 
emphasized that pursuing IVIVC should be generally 
encouraged, considering its high value from both 
industry and regulators' perspective. Both industry and 
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regulatory authorities will benefit from a standardized 
biopredictive dissolution model that can establish 
IVIVC/IVIVR for different kinds of oral drug products. 
Regarding disintegration aspects for oral drug products, 
Peter Langguth demonstrated some case examples to 
show the audience that (i) the current pharmacopoeial 
disintegration tester can be modified for a better in vivo 
prediction and (ii) biopredictive disintegration methods 
in combination with dissolution data may help explain 
unexpected in vivo pharmacokinetic findings, such as 
food effects and effects of tablet crushing on dissolution 
of the drug.
The last day of the conference highlighted the evolution 
of generic drug development from the 1970s until now. 
Lawrence Yu brought to our attention how BE studies are 
evolving from an arbitrary to a more statistical design. A 
comparison was established between average BE criteria, 
using 80–125% limits on the 90% confidence intervals 
for Cmax and AUC geometric mean ratios, and a scaled 
average BE (i.e., tightened BE limits including within-
subject variability). Especially in the case of highly variable 
drug products (within-subject variability with CV ≥ 30%) 
and narrow therapeutic drug products, a scaled average 
BE is a good statistical and rational approach for the 
evaluation of the BE (17–20). In case of modified release 
dosage forms, multiphasic PK behavior (showing more 
than one peak/shoulder in the concentration profile) may 
be seen. If so, the traditional metrics of AUC and Cmax 
may not be sufficient to ensure BE. In addition to the 
traditional PK parameters of AUCinf and Cmax, partial 
AUC (pAUC; AUC0-1.5h and AUC1.5-t) measurements are 
recommended to provide BE measures with respect to 
label indications (21). This was thoroughly explored and 
discussed for zolpidem tartrate extended-release tablets 
(Ambien CR®) with an immediate-release layer on the 
outside of the tablet and a controlled-release layer on the 
inside. The rationale behind this formulation strategy is to 
launch a direct sleep onset followed by a sustained period 
for sleep maintenance. Regarding BE for delayed-release 
drug products, Peter Langguth and Jozef Al-Gousous 
observed that enteric-coated dosage forms frequently do 
not rapidly dissolve following gastric emptying and, thus, 
the pharmacokinetic lag-time does not only reflect the 
gastric emptying process (22). 
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